This week, the top news in managed care included top health care takeaways from the 2020 general election; a Q&A with Dr William Shrank on connecting Medicare Advantage providers and patients; Managed Care Cast discusses balancing evidence with action amid the COVID-19 pandemic.
Top health care takeaways from the 2020 general election, a Q&A with Dr William Shrank on connecting Medicare Advantage providers and patients, and Managed Care Cast discusses balancing evidence with action amid the COVID-19 pandemic.
Welcome to This Week in Managed Care, I’m Matthew Gavidia.
Top 5 Health Care Takeaways From the 2020 General Election
As of 11 AM Eastern on Friday, it appears likely that former Vice President Joe Biden will be the next president of United States, as he leads in Pennsylvania, although ballots are still being counted.
In addition, voters weighed in on several ballot measures and state level races that yielded results with major implications in the health care field.
This week, over 60% of Louisiana voters approved an amendment proposing adding language to the state’s constitution ensuring it does not protect abortion as a right. The language also mandates abortion is not to be funded except in cases of life endangerment.
Specifically, a vote for Amendment 1 added this sentence to the Louisiana Declaration of Rights: “To protect human life, nothing in this constitution shall be construed to secure or protect a right to abortion or require the funding of abortion."
Conversely, voters in Colorado rejected Proposition 115, which aimed to outlaw abortions after 22 weeks of pregnancy with exceptions for life-threatening situations. The American College of Obstetricians & Gynecologists also opposed the proposition, claiming it would interfere with the doctor-patient relationship and complicate medical decisions.
In another notable health care–related outcome of the 2020 elections, Oregon became the first state to decriminalize the possession of small amounts of street drugs, including cocaine, methamphetamine, and heroin.
The new drug initiative will permit individuals arrested with small amounts of these drugs to avoid going to trial and possible jail time. Instead, individuals will pay a $100 fine and attend an addiction recovery program, while centers will be funded by revenue gained from sales of recreational marijuana.
For more, visit ajmc.com.
Medicare Advantage Providers, Patients Connect Without a Playbook
To mark the 25th anniversary of The American Journal of Managed Care®, we spoke with Dr William H. Shrank, chief medical officer of Humana, on several health care–related topics, particularly challenges to providing value-based care amid the COVID-19 pandemic.
“I would say there’s a tremendous amount of uncertainty right now,” said Shrank. “There’s a lot that we can’t predict accurately with respect to the trajectory of the pandemic.”
Shrank noted that during this time, his organization’s affiliated partners are looking for a path to resiliency, with many exploring new ways of contracting with Humana from a value-based perspective.
“Our approach is to work really closely with our providers and try to understand how we can be part of the solution: to help them, and to help them help our members through these really uncertain times,” said Shrank.
For the full interview, visit ajmc.com.
Balancing Evidence With Action: Dr Patricia Salber Interviews Dr Denise Basow
In this week’s Managed Care Cast, Dr Patricia Salber, of The Doctor Weighs In, spoke with Dr Denise Basow, president and CEO of clinical effectiveness at Wolters Kluwer, on balancing evidence-based science with action amid the pandemic.
As a global provider of professional information for groups such as clinicians and regulatory sectors, Basow described how her organization has worked to advise clients on all COVID-19–related aspects, which seemingly change by the day.
In speaking on this onslaught of novel information, Basow addresses the risk of misinformation, the wide range of information sources available, and much more.
For the full interview, visit ajmc.com.
Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression
This past week, Regeneron’s PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was accepted for priority review by the FDA for the treatment of first-line locally advanced or metastatic non–small cell lung cancer with PD-L1 expression of at least 50%.
The supplemental Biologics License Application accepted for review, which has a target decision date of February 28, 2021, is based on results from the EMPOWER-Lung 1 trial of cemiplimab monotherapy vs platinum-doublet chemotherapy.
The randomized, phase 3, open-label trial separated 710 patients with advanced non–small cell lung cancer into 2 cohorts, with 1 group receiving cemiplimab and the other undergoing standard-of-care chemotherapy.
In comparison with the chemotherapy group, the cemiplimab cohort exhibited:
In addition to the FDA review, the European Medicines Agency is assessing the drug for the same indication, with a decision anticipated in the second quarter of 2021.
For more, visit ajmc.com.
Paper of the Week
And, now our paper of the week, which looks back at some of the most important papers over the past 25 years of The American Journal of Managed Care® and why they matter today.
Patterns of chemotherapy use in lung cancer and the related costs were the topic of a 2008 paper, led by Dr Scott Ramsey of the University of Washington.
A claims analysis found that second- and third-line chemotherapy were prescribed relatively infrequently at that time; of the patients who had first-line chemotherapy, a quarter had second-line therapy and only 10% had third-line therapy. Direct medical costs increased substantially with each treatment, especially if the therapy was used off-label.
This paper appeared in the era before clinical pathways, and payment reform encouraged more stratification in care.
For the paper, visit ajmc.com.
For all of us at AJMC®, I’m Matthew Gavidia. Thanks for joining us!
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Medicaid, Medicare Policy Changes Could Lead to More Than 25,000 Additional Deaths, Study Says
April 30th 2024Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.
Read More